Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT00878423

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00878423. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.

Study identification

NCT ID: NCT00878423
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Metastatic Solid Tumors

Interventions

AT13387 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2008 (Type not available)
Primary completion: May 2013 (Actual)
Completion: Mar 2014 (Actual)
Last update posted: Aug 2, 2024

2008 – 2014

United States locations

U.S. sites: 4
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
The University of Arizona Cancer Center	Tucson	Arizona	85724-5024	—
Massachusetts General Hospital	Boston	Massachusetts	02114-2696	—
Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00878423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 2, 2024 · Synced Nov 12, 2026